Limited Amounts of Dendritic Cells Migrate into the T-Cell Area of Lymph Nodes but Have High Immune Activating Potential in Melanoma Patients

• Published in: Clinical cancer research Vol. 15; no. 7; pp. 2531 - 2540
• Main Authors: VERDIJK, Pauline, AARNTZEN, Erik H. J. G, BLOKX, Willeke, VAN KRIEKEN, J. Han J. M, JOOSTEN, Irma, BOERMAN, Otto C, OYEN, Wim J. G, ADEMA, Gosse, PUNT, Cornelis J. A, FIGDOR, Carl G, DE VRIES, I. Jolanda M, JOOST LESTERHUIS, W, INGE BOULLART, A. C, KOK, Ellemieke, VAN ROSSUM, Michelle M, STRIJK, Simon, EIJCKELER, Femke, BONENKAMP, Johannes J, JACOBS, Joannes F. M
• Format: Journal Article
• Language: English
• Published: Philadelphia, PA American Association for Cancer Research 01.04.2009
• Subjects: Antineoplastic agents; Biological and medical sciences; Cancer Vaccines - administration & dosage; Cancer Vaccines - pharmacokinetics; Cell Movement; dendritic cells; Dendritic Cells - immunology; Dendritic Cells - transplantation; Dermatology; Humans; immunotherapy; Injections; lymph nodes; Lymph Nodes - immunology; Lymphocyte Activation; Medical sciences; Melanoma - immunology; Melanoma - metabolism; Phagocytosis; Pharmacology. Drug treatments; Skin Neoplasms - immunology; Skin Neoplasms - metabolism; T-Lymphocytes - immunology; Tumors of the skin and soft tissue. Premalignant lesions; Human; Dendritic cell; Lymph node; Antigen presenting cell; T-Lymphocyte; Malignant melanoma; Patient; Malignant tumor; Cancer

Purpose: The success of immunotherapy with dendritic cells (DC) to treat cancer is dependent on effective migration to the lymph nodes and subsequent activation of antigen-specific T cells. In this study, we investigated the fate of DC after intradermal (i.d.) or intranodal (i.n.) administration and...